-
1
-
-
78649639988
-
Hotline sessions and clinical trial updates presented at the European Society of Cardiology Congress in Stockholm 2010
-
M Lenski F Mahfoud C Werner A Bauer M Böhm 2010 Hotline sessions and clinical trial updates presented at the European Society of Cardiology Congress in Stockholm 2010 Clin Res Cardiol Off J Ger Card Soc 99 679 692
-
(2010)
Clin Res Cardiol off J Ger Card Soc
, vol.99
, pp. 679-692
-
-
Lenski, M.1
Mahfoud, F.2
Werner, C.3
Bauer, A.4
Böhm, M.5
-
2
-
-
80053563341
-
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): A prospective epidemiological survey
-
doi: 10.1016/S0140-6736(11)61215-4
-
Yusuf S. Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L, Wei L, Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, Zatonski W, Rosengren A, Teo KK, on behalf of the Prospective Urban Rural Epidemiology (PURE) Study Investigators (2011) Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. doi: 10.1016/S0140-6736(11)61215-4
-
(2011)
Lancet
-
-
Yusuf, S.1
Islam, S.2
Chow, C.K.3
Rangarajan, S.4
Dagenais, G.5
Diaz, R.6
Gupta, R.7
Kelishadi, R.8
Iqbal, R.9
Avezum, A.10
Kruger, A.11
Kutty, R.12
Lanas, F.13
Lisheng, L.14
Wei, L.15
Lopez-Jaramillo, P.16
Oguz, A.17
Rahman, O.18
Swidan, H.19
Yusoff, K.20
Zatonski, W.21
Rosengren, A.22
Teo, K.K.23
more..
-
3
-
-
70450081001
-
Major lipids, apolipoproteins, and risk of vascular disease
-
19903920 10.1001/jama.2009.1619 1:CAS:528:DC%2BD1MXhsVSktLjN
-
E Di Angelantonio N Sarwar P Perry S Kaptoge KK Ray A Thompson AM Wood S Lewington N Sattar CJ Packard R Collins SG Thompson J Danesh 2009 Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 1993 2000 19903920 10.1001/jama.2009.1619 1:CAS:528:DC%2BD1MXhsVSktLjN
-
(2009)
JAMA
, vol.302
, pp. 1993-2000
-
-
Di Angelantonio, E.1
Sarwar, N.2
Perry, P.3
Kaptoge, S.4
Ray, K.K.5
Thompson, A.6
Wood, A.M.7
Lewington, S.8
Sattar, N.9
Packard, C.J.10
Collins, R.11
Thompson, S.G.12
Danesh, J.13
-
5
-
-
0018649439
-
Atherogenesis: A postprandial phenomenon
-
DB Zilversmit 1979 Atherogenesis: a postprandial phenomenon Circulation 60 473 485 222498 1:CAS:528:DyaE1MXlsFGntLc%3D (Pubitemid 9254048)
-
(1979)
Circulation
, vol.60
, Issue.3
, pp. 473-485
-
-
Zilversmit, D.B.1
-
6
-
-
80052836882
-
A new era for anticoagulation in atrial fibrillation
-
doi: 10.1056/NEJMe1109748
-
Mega JL (2011) A new era for anticoagulation in atrial fibrillation. N Engl J Med. doi: 10.1056/NEJMe1109748
-
(2011)
N Engl J Med.
-
-
Mega, J.L.1
-
7
-
-
70349306707
-
Dabigatran versus warfarin in patients with atrial fibrillation
-
RE-LY Steering Committee and Investigators. 19717844 10.1056/ NEJMoa0905561 1:CAS:528:DC%2BD1MXhtFOjsLnN
-
SJ Connolly MD Ezekowitz S Yusuf J Eikelboom J Oldgren A Parekh J Pogue PA Reilly E Themeles J Varrone S Wang M Alings D Xavier J Zhu R Diaz BS Lewis H Darius HC Diener CD Joyner L Wallentin RE-LY Steering Committee and Investigators 2009 Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 1139 1151 19717844 10.1056/NEJMoa0905561 1:CAS:528:DC%2BD1MXhtFOjsLnN
-
(2009)
N Engl J Med
, vol.361
, pp. 1139-1151
-
-
Connolly, S.J.1
Ezekowitz, M.D.2
Yusuf, S.3
Eikelboom, J.4
Oldgren, J.5
Parekh, A.6
Pogue, J.7
Reilly, P.A.8
Themeles, E.9
Varrone, J.10
Wang, S.11
Alings, M.12
Xavier, D.13
Zhu, J.14
Diaz, R.15
Lewis, B.S.16
Darius, H.17
Diener, H.C.18
Joyner, C.D.19
Wallentin, L.20
more..
-
8
-
-
80052592404
-
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
-
ROCKET AF Investigators. 21830957 10.1056/NEJMoa1009638 1:CAS:528:DC%2BC3MXhtFKhsLnI
-
MR Patel KW Mahaffey J Garg G Pan DE Singer W Hacke G Breithardt JL Halperin GJ Hankey JP Piccini RC Becker CC Nessel JF Paolini SD Berkowitz KA Fox RM Califf ROCKET AF Investigators 2011 Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 883 891 21830957 10.1056/NEJMoa1009638 1:CAS:528:DC%2BC3MXhtFKhsLnI
-
(2011)
N Engl J Med
, vol.365
, pp. 883-891
-
-
Patel, M.R.1
Mahaffey, K.W.2
Garg, J.3
Pan, G.4
Singer, D.E.5
Hacke, W.6
Breithardt, G.7
Halperin, J.L.8
Hankey, G.J.9
Piccini, J.P.10
Becker, R.C.11
Nessel, C.C.12
Paolini, J.F.13
Berkowitz, S.D.14
Fox, K.A.15
Califf, R.M.16
-
9
-
-
80052825103
-
Apixaban versus warfarin in patients with atrial fibrillation
-
doi: 10.1056/NEJMoa1107039
-
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. doi: 10.1056/NEJMoa1107039
-
(2011)
N Engl J Med.
-
-
Granger, C.B.1
Alexander, J.H.2
McMurray, J.J.3
Lopes, R.D.4
Hylek, E.M.5
Hanna, M.6
Al-Khalidi, H.R.7
Ansell, J.8
Atar, D.9
Avezum, A.10
Bahit, M.C.11
Diaz, R.12
Easton, J.D.13
Ezekowitz, J.A.14
Flaker, G.15
Garcia, D.16
Geraldes, M.17
Gersh, B.J.18
Golitsyn, S.19
Goto, S.20
Hermosillo, A.G.21
Hohnloser, S.H.22
Horowitz, J.23
Mohan, P.24
Jansky, P.25
Lewis, B.S.26
Lopez-Sendon, J.L.27
Pais, P.28
Parkhomenko, A.29
Verheugt, F.W.30
Zhu, J.31
Wallentin, L.32
more..
-
10
-
-
77649249878
-
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: Design and rationale
-
ARISTOTLE Investigators. 20211292 10.1016/j.ahj.2009.07.035 1:CAS:528:DC%2BC3cXivFWgur8%3D
-
RD Lopes JH Alexander SM Al-Khatib J Ansell R Diaz JD Easton BJ Gersh CB Granger M Hanna J Horowitz EM Hylek JJ McMurray FW Verheugt L Wallentin ARISTOTLE Investigators 2010 Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale Am Heart J 159 331 339 20211292 10.1016/j.ahj.2009.07.035 1:CAS:528:DC%2BC3cXivFWgur8%3D
-
(2010)
Am Heart J
, vol.159
, pp. 331-339
-
-
Lopes, R.D.1
Alexander, J.H.2
Al-Khatib, S.M.3
Ansell, J.4
Diaz, R.5
Easton, J.D.6
Gersh, B.J.7
Granger, C.B.8
Hanna, M.9
Horowitz, J.10
Hylek, E.M.11
McMurray, J.J.12
Verheugt, F.W.13
Wallentin, L.14
-
12
-
-
85046981523
-
Colchicine for recurrent pericarditis (CORP) a randomized trial
-
doi: 10.2459/JCM.0b013e3280110616
-
Imazio M, Brucato A, Cemin R, Ferrua S, Belli R, Maestroni S, Trinchero R, Spodick DH, Adler Y, on behalf of the CORP (COlchicine for Recurrent Pericarditis) Investigators (2011) Colchicine for recurrent pericarditis (CORP) a randomized trial. Ann Intern Med. doi: 10.2459/JCM.0b013e3280110616
-
(2011)
Ann Intern Med.
-
-
Imazio, M.1
Brucato, A.2
Cemin, R.3
Ferrua, S.4
Belli, R.5
Maestroni, S.6
Trinchero, R.7
Spodick, D.H.8
Adler, Y.9
-
13
-
-
73849084830
-
Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study
-
KYOTO HEART Study Group. 19723695 10.1093/eurheartj/ehp363 1:CAS:528:DC%2BD1MXht12ht7vL
-
T Sawada H Yamada B Dahlöf H Matsubara KYOTO HEART Study Group 2009 Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study Eur Heart J 30 2461 2469 19723695 10.1093/eurheartj/ehp363 1:CAS:528:DC%2BD1MXht12ht7vL
-
(2009)
Eur Heart J
, vol.30
, pp. 2461-2469
-
-
Sawada, T.1
Yamada, H.2
Dahlöf, B.3
Matsubara, H.4
-
14
-
-
0006456524
-
NKF-DOQI clinical practice guidelines for hemodialysis adequacy. National Kidney Foundation
-
NK Foundation 1997 NKF-DOQI clinical practice guidelines for hemodialysis adequacy. National Kidney Foundation Am J kidney Dis Off J Natl Kidney Found 30 3 Suppl 2 S15 S66
-
(1997)
Am J Kidney Dis off J Natl Kidney Found
, vol.30
, Issue.3 SUPPL. 2
-
-
Foundation, N.K.1
-
15
-
-
74549183897
-
Angiotensin receptor blockers: Baseline therapy in hypertension?
-
19723696 10.1093/eurheartj/ehp364
-
FH Messerli S Bangalore F Ruschitzka 2009 Angiotensin receptor blockers: baseline therapy in hypertension? Eur Heart J 30 2427 2430 19723696 10.1093/eurheartj/ehp364
-
(2009)
Eur Heart J
, vol.30
, pp. 2427-2430
-
-
Messerli, F.H.1
Bangalore, S.2
Ruschitzka, F.3
-
16
-
-
0037420492
-
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial
-
DOI 10.1016/S0140-6736(03)12948-0
-
PS Sever, et al. 2003 Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 9364 1149 1158 12686036 10.1016/S0140-6736(03)12948-0 1:CAS:528:DC%2BD3sXis1yqu7o%3D (Pubitemid 36398384)
-
(2003)
Lancet
, vol.361
, Issue.9364
, pp. 1149-1158
-
-
Sever, P.S.1
Dahlof, B.2
Poulter, N.R.3
Wedel, H.4
Beevers, G.5
Caulfield, M.6
Collins, R.7
Kjeldsen, S.E.8
Kristinsson, A.9
McInnes, G.T.10
Mehlsen, J.11
Nieminen, M.12
O'Brien, E.13
Ostergren, J.14
-
17
-
-
80054741504
-
The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK
-
doi: 10.1093/eurheartj/ehr333
-
Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR, on behalf of the ASCOT Investigators (2011) The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. Eur Heart J. doi: 10.1093/eurheartj/ehr333
-
(2011)
Eur Heart J.
-
-
Sever, P.S.1
Chang, C.L.2
Gupta, A.K.3
Whitehouse, A.4
Poulter, N.R.5
-
19
-
-
80054071757
-
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
-
doi: 10.1093/eurheartj/ehr342
-
Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM (2011) Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. doi: 10.1093/eurheartj/ehr342
-
(2011)
Eur Heart J.
-
-
Fox, K.A.1
Piccini, J.P.2
Wojdyla, D.3
Becker, R.C.4
Halperin, J.L.5
Nessel, C.C.6
Paolini, J.F.7
Hankey, G.J.8
Mahaffey, K.W.9
Patel, M.R.10
Singer, D.E.11
Califf, R.M.12
-
20
-
-
42049107348
-
Telmisartan, ramipril, or both in patients at high risk for vascular events
-
DOI 10.1056/NEJMoa0801317
-
S Yusuf KK Teo J Pogue L Dyal I Copland H Schumacher G Dagenais P Sleight C Anderson 2008 Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 1547 1559 18378520 10.1056/NEJMoa0801317 1:CAS:528:DC%2BD1cXksF2isLs%3D (Pubitemid 351522739)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.15
, pp. 1547-1559
-
-
Yusuf, S.1
Teo, K.K.2
Pogue, J.3
Dyal, L.4
Copland, I.5
Schumacher, H.6
Dagenais, G.7
Sleight, P.8
Anderson, C.9
-
21
-
-
78650399880
-
Eplerenone in patients with systolic heart failure and mild symptoms
-
EMPHASIS-HF Study Group. 21073363 10.1056/NEJMoa1009492 1:CAS:528:DC%2BC3MXisValuw%3D%3D
-
F Zannad JJ McMurray H Krum DJ van Veldhuisen K Swedberg H Shi J Vincent SJ Pocock B Pitt EMPHASIS-HF Study Group 2011 Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 11 21 21073363 10.1056/NEJMoa1009492 1:CAS:528:DC%2BC3MXisValuw%3D%3D
-
(2011)
N Engl J Med
, vol.364
, pp. 11-21
-
-
Zannad, F.1
McMurray, J.J.2
Krum, H.3
Van Veldhuisen, D.J.4
Swedberg, K.5
Shi, H.6
Vincent, J.7
Pocock, S.J.8
Pitt, B.9
-
22
-
-
2442479695
-
Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure
-
DOI 10.1056/NEJMoa032423
-
MR Bristow LA Saxon J Boehmer S Krueger DA Kass T De Marco P Carson L DiCarlo D DeMets BG White DW DeVries AM Feldman 2004 Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure N Engl J Med 350 2140 2150 15152059 10.1056/NEJMoa032423 1:CAS:528:DC%2BD2cXktF2isrc%3D (Pubitemid 38637994)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.21
-
-
Bristow, M.R.1
Saxon, L.A.2
Boehmer, J.3
Krueger, S.4
Kass, D.A.5
De Marco, T.6
Carson, P.7
DiCarlo, L.8
DeMets, D.9
White, B.G.10
DeVries, D.W.11
Feldman, A.M.12
-
23
-
-
16844364826
-
The effect of cardiac resynchronization on morbidity and mortality in heart failure
-
DOI 10.1056/NEJMoa050496
-
JG Cleland JC Daubert E Erdmann N Freemantle D Gras L Kappenberger Tavazzi Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators 2005 The effect of cardiac resynchronization on morbidity and mortality in heart failure N Engl J Med 352 1539 1549 15753115 10.1056/NEJMoa050496 1:CAS:528:DC%2BD2MXjtFGnsLo%3D (Pubitemid 40517094)
-
(2005)
New England Journal of Medicine
, vol.352
, Issue.15
, pp. 1539-1549
-
-
Cleland, J.G.F.1
Daubert, J.-C.2
Erdmann, E.3
Freemantle, N.4
Gras, D.5
Kappenberger, L.6
Tavazzi, L.7
-
24
-
-
56349114416
-
Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heartfailure symptoms
-
REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group. 19038680 10.1016/j.jacc.2008.08.027
-
C Linde WT Abraham MR Gold M St John Sutton S Ghio C Daubert REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group 2008 Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heartfailure symptoms J Am Coll Cardiol 52 1834 1843 19038680 10.1016/j.jacc.2008.08.027
-
(2008)
J Am Coll Cardiol
, vol.52
, pp. 1834-1843
-
-
Linde, C.1
Abraham, W.T.2
Gold, M.R.3
St John Sutton, M.4
Ghio, S.5
Daubert, C.6
-
25
-
-
70349625757
-
Cardiac-resynchronization therapy for the prevention of heart-failure events
-
MADIT-CRT Trial Investigators. 19723701 10.1056/NEJMoa0906431
-
AJ Moss WJ Hall DS Cannom H Klein MW Brown JP Daubert NA Estes 3rd E Foster H Greenberg SL Higgins MA Pfeffer SD Solomon D Wilber W Zareba MADIT-CRT Trial Investigators 2009 Cardiac-resynchronization therapy for the prevention of heart-failure events N Engl J Med 361 1329 1338 19723701 10.1056/NEJMoa0906431
-
(2009)
N Engl J Med
, vol.361
, pp. 1329-1338
-
-
Moss, A.J.1
Hall, W.J.2
Cannom, D.S.3
Klein, H.4
Brown, M.W.5
Daubert, J.P.6
Estes III, N.A.7
Foster, E.8
Greenberg, H.9
Higgins, S.L.10
Pfeffer, M.A.11
Solomon, S.D.12
Wilber, D.13
Zareba, W.14
-
26
-
-
67650093472
-
Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: A sub-analysis of the CARE-HF trial
-
19505883 10.1093/eurjhf/hfp074
-
R Gervais C Leclercq A Shankar S Jacobs H Eiskjaer A Hagemann N Freemantle J Cleland L Tavazzi C Daubert 2009 Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a sub-analysis of the CARE-HF trial Eur J Heart Fail 11 699 705 19505883 10.1093/eurjhf/hfp074
-
(2009)
Eur J Heart Fail
, vol.11
, pp. 699-705
-
-
Gervais, R.1
Leclercq, C.2
Shankar, A.3
Jacobs, S.4
Eiskjaer, H.5
Hagemann, A.6
Freemantle, N.7
Cleland, J.8
Tavazzi, L.9
Daubert, C.10
-
27
-
-
78650700438
-
Primary results from the SmartDelay determined AV optimization: A comparison to other AV delay methods used in Cardiac Resynchronization Therapy (SMART-AV) trial
-
21098426 10.1161/CIRCULATIONAHA.110.992552
-
KA Ellenbogen MR Gold TE Meyer IF Lozano S Mittal AD Waggoner B Lemke JP Singh FG Spinale J Van Eyk J Whitehill S Weiner M Bedi J Rapkin KM Stein 2010 Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in Cardiac Resynchronization Therapy (SMART-AV) trial Circulation 122 2660 2668 21098426 10.1161/CIRCULATIONAHA.110.992552
-
(2010)
Circulation
, vol.122
, pp. 2660-2668
-
-
Ellenbogen, K.A.1
Gold, M.R.2
Meyer, T.E.3
Lozano, I.F.4
Mittal, S.5
Waggoner, A.D.6
Lemke, B.7
Singh, J.P.8
Spinale, F.G.9
Van Eyk, J.10
Whitehill, J.11
Weiner, S.12
Bedi, M.13
Rapkin, J.14
Stein, K.M.15
-
28
-
-
80054070561
-
Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: Results from the SHIFT study
-
doi: 10.1093/eurheartj/ehr343
-
Ekman I, Chassany O, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Swedberg K (2011) Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. doi: 10.1093/eurheartj/ehr343
-
(2011)
Eur Heart J.
-
-
Ekman I, C.1
-
29
-
-
79955494359
-
Coronary-artery bypass surgery in patients with left ventricular dysfunction
-
STICH Investigators. 21463150 10.1056/NEJMoa1100356 1:CAS:528: DC%2BC3MXlsFeltr4%3D
-
EJ Velazquez KL Lee MA Deja A Jain G Sopko A Marchenko IS Ali G Pohost S Gradinac WT Abraham M Yii D Prabhakaran H Szwed P Ferrazzi MC Petrie CM O'Connor P Panchavinnin L She RO Bonow GR Rankin RH Jones JL Rouleau STICH Investigators 2011 Coronary-artery bypass surgery in patients with left ventricular dysfunction N Engl J Med 364 1607 1616 21463150 10.1056/NEJMoa1100356 1:CAS:528:DC%2BC3MXlsFeltr4%3D
-
(2011)
N Engl J Med
, vol.364
, pp. 1607-1616
-
-
Velazquez, E.J.1
Lee, K.L.2
Deja, M.A.3
Jain, A.4
Sopko, G.5
Marchenko, A.6
Ali, I.S.7
Pohost, G.8
Gradinac, S.9
Abraham, W.T.10
Yii, M.11
Prabhakaran, D.12
Szwed, H.13
Ferrazzi, P.14
Petrie, M.C.15
O'Connor, C.M.16
Panchavinnin, P.17
She, L.18
Bonow, R.O.19
Rankin, G.R.20
Jones, R.H.21
Rouleau, J.L.22
more..
-
30
-
-
0037179656
-
Warfarin, aspirin, or both after myocardial infarction
-
12324552 10.1056/NEJMoa020496 1:CAS:528:DC%2BD38Xnt12rtLY%3D
-
M Hurlen M Abdelnoor P Smith J Erikssen H Arnesen 2002 Warfarin, aspirin, or both after myocardial infarction N Engl J Med 347 969 974 12324552 10.1056/NEJMoa020496 1:CAS:528:DC%2BD38Xnt12rtLY%3D
-
(2002)
N Engl J Med
, vol.347
, pp. 969-974
-
-
Hurlen, M.1
Abdelnoor, M.2
Smith, P.3
Erikssen, J.4
Arnesen, H.5
-
31
-
-
0035899289
-
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
-
DOI 10.1056/NEJMoa010746
-
S Yusuf F Zhao SR Mehta S Chrolavicius G Tognoni KK Fox Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators 2001 Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 494 502 11519503 10.1056/NEJMoa010746 1:CAS:528:DC%2BD3MXms1arsrY%3D (Pubitemid 32758501)
-
(2001)
New England Journal of Medicine
, vol.345
, Issue.7
, pp. 494-502
-
-
Yusuf, S.1
Zhao, F.2
Mehta, S.R.3
Chrolavicius, S.4
Tognoni, G.5
Fox, K.K.6
-
32
-
-
71749087343
-
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: A retrospective analysis of nationwide registry data
-
20006130 10.1016/S0140-6736(09)61751-7
-
R Sørensen ML Hansen SZ Abildstrom A Hvelplund C Andersson C Jørgensen JK Madsen PR Hansen L Køber C Torp-Pedersen GH Gislason 2009 Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data Lancet 374 1967 1974 20006130 10.1016/S0140-6736(09)61751-7
-
(2009)
Lancet
, vol.374
, pp. 1967-1974
-
-
Sørensen, R.1
Hansen, M.L.2
Abildstrom, S.Z.3
Hvelplund, A.4
Andersson, C.5
Jørgensen, C.6
Madsen, J.K.7
Hansen, P.R.8
Køber, L.9
Torp-Pedersen, C.10
Gislason, G.H.11
-
33
-
-
80051834654
-
Novel oral anticoagulants: Focus on stroke prevention and treatment of venous thromboembolism
-
doi: 10.1093/eurheartj/ehr052
-
Steffel J, Braunwald E (2011) Novel oral anticoagulants: focus on stroke prevention and treatment of venous thromboembolism. Eur Heart J. doi: 10.1093/eurheartj/ehr052
-
(2011)
Eur Heart J.
-
-
Steffel, J.1
Braunwald, E.2
-
34
-
-
80054733922
-
RUBY-1: A randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome
-
doi: 10.1093/eurheartj/ehr334
-
Steg PG, Mehta S, Jukema JV, Lip GYH, Gibson CM, Kovar F, Kala P, Garcia-Hernandez A, Renfurm RW, Granger CB (2011) RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J. doi: 10.1093/eurheartj/ehr334
-
(2011)
Eur Heart J.
-
-
Steg, P.G.1
Mehta, S.2
Jukema, J.V.3
Gyh, L.4
Gibson, C.M.5
Kovar, F.6
Kala, P.7
Garcia-Hernandez, A.8
Renfurm, R.W.9
Granger, C.B.10
-
35
-
-
67649563209
-
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial
-
APPRAISE Steering Committee and Investigators. 19470889 10.1161/CIRCULATIONAHA.108.832139
-
APPRAISE Steering Committee and Investigators JH Alexander RC Becker DL Bhatt F Cools F Crea M Dellborg KA Fox SG Goodman RA Harrington K Huber S Husted BS Lewis J Lopez-Sendon P Mohan G Montalescot M Ruda W Ruzyllo F Verheugt Wallentin 2009 Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial Circulation 119 2877 2885 19470889 10.1161/CIRCULATIONAHA.108.832139
-
(2009)
Circulation
, vol.119
, pp. 2877-2885
-
-
Alexander, J.H.1
Becker, R.C.2
Bhatt, D.L.3
Cools, F.4
Crea, F.5
Dellborg, M.6
Fox, K.A.7
Goodman, S.G.8
Harrington, R.A.9
Huber, K.10
Husted, S.11
Lewis, B.S.12
Lopez-Sendon, J.13
Mohan, P.14
Montalescot, G.15
Ruda, M.16
Ruzyllo, W.17
Verheugt, F.18
Wallentin19
-
36
-
-
80052162121
-
Apixaban with antiplatelet therapy after acute coronary syndrome
-
doi: 10.1056/nejmoa1105819nejm.org
-
Alexander, JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina, R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington, RH, Wallentin L, for the APPRAISE-2 Investigators (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. doi: 10.1056/nejmoa1105819nejm.org
-
(2011)
N Engl J Med.
-
-
Alexander, J.H.1
Lopes, R.D.2
James, S.3
Kilaru, R.4
He, Y.5
Mohan, P.6
Bhatt, D.L.7
Goodman, S.8
Verheugt, F.W.9
Flather, M.10
Huber, K.11
Liaw, D.12
Husted, S.E.13
Lopez-Sendon, J.14
De Caterina, R.15
Jansky, P.16
Darius, H.17
Vinereanu, D.18
Cornel, J.H.19
Cools, F.20
Atar, D.21
Leiva-Pons, J.L.22
Keltai, M.23
Ogawa, H.24
Pais, P.25
Parkhomenko, A.26
Ruzyllo, W.27
Diaz, R.28
White, H.29
Ruda, M.30
Geraldes, M.31
Lawrence, J.32
Harrington, R.H.33
Wallentin, L.34
more..
-
37
-
-
67649562905
-
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial
-
ATLAS ACS-TIMI 46 study group. 19539361 10.1016/S0140-6736(09)60738-8 1:CAS:528:DC%2BD1MXotFCgtLc%3D
-
JL Mega E Braunwald S Mohanavelu P Burton R Poulter F Misselwitz V Hricak ES Barnathan P Bordes A Witkowski V Markov L Oppenheimer CM Gibson ATLAS ACS-TIMI 46 study group 2009 Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial Lancet 374 29 38 19539361 10.1016/S0140-6736(09)60738-8 1:CAS:528:DC%2BD1MXotFCgtLc%3D
-
(2009)
Lancet
, vol.374
, pp. 29-38
-
-
Mega, J.L.1
Braunwald, E.2
Mohanavelu, S.3
Burton, P.4
Poulter, R.5
Misselwitz, F.6
Hricak, V.7
Barnathan, E.S.8
Bordes, P.9
Witkowski, A.10
Markov, V.11
Oppenheimer, L.12
Gibson, C.M.13
-
38
-
-
79955887785
-
Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome
-
21570509 10.1016/j.ahj.2011.01.026 1:CAS:528:DC%2BC3MXmtFansLY%3D
-
CM Gibson JL Mega P Burton S Goto F Verheugt C Bode A Plotnikov X Sun N Cook-Bruns E Braunwald 2011 Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome Am Heart J 161 815 821 21570509 10.1016/j.ahj.2011.01.026 1:CAS:528: DC%2BC3MXmtFansLY%3D
-
(2011)
Am Heart J
, vol.161
, pp. 815-821
-
-
Gibson, C.M.1
Mega, J.L.2
Burton, P.3
Goto, S.4
Verheugt, F.5
Bode, C.6
Plotnikov, A.7
Sun, X.8
Cook-Bruns, N.9
Braunwald, E.10
-
39
-
-
77955966357
-
Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention: A randomized controlled trial
-
BCIS-1 Investigators. 20736470 10.1001/jama.2010.1190 1:CAS:528:DC%2BC3cXhtVOksr%2FK
-
D Perera R Stables M Thomas J Booth M Pitt D Blackman A de Belder S Redwood BCIS-1 Investigators 2010 Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention: a randomized controlled trial JAMA 304 867 874 20736470 10.1001/jama.2010.1190 1:CAS:528: DC%2BC3cXhtVOksr%2FK
-
(2010)
JAMA
, vol.304
, pp. 867-874
-
-
Perera, D.1
Stables, R.2
Thomas, M.3
Booth, J.4
Pitt, M.5
Blackman, D.6
De Belder, A.7
Redwood, S.8
|